范德尔研究所进行的EVITA第二阶段临床试验表明，每天口服1000毫克维生素C可能为患有前癌性血液疾病患者带来生存益处。1这项随机、双盲、安慰剂对照试验招募了109名患有未确定意义的克隆性细胞减少症（CCUS）或骨髓异常增生综合征（MDS）的患者，参与者连续12个月每日补充维生素C。1约三年的随访结果显示，接受维生素C补充的患者生存率明显高于安慰剂组，同时不良事件发生率更低。1
试验发现，超过一半的参与者在试验开始时维生素C水平不足。1研究人员指出，虽然维生素C补充未能明显影响异常血细胞的扩增率，但呈现出令人鼓舞的生存优势。1这项研究在哥本哈根大学医院-Rigshospitalet、哥本哈根大学医院-Herlev、奥尔堡大学医院和南加州大学凯克医院四家机构进行。1研究人员强调，需要进行更大规模的第三阶段临床试验来进一步验证这一潜在的生存获益。1该研究结果已发表在美国癌症协会期刊《CANCER》上。1
Researchers from Vanderbilt Institute have released findings from the EVITA Phase II clinical trial demonstrating that daily oral supplementation of 1,000 milligrams of vitamin C may benefit patients with clonal cytopenias of undetermined significance (CCUS) and myelodysplastic syndromes (MDS), precancerous blood conditions and early blood cancers.1 The trial enrolled 109 patients who received vitamin C supplements for 12 months, and those receiving the supplement experienced fewer adverse events and significantly higher survival rates after approximately three years of follow-up compared to the placebo group.1
The EVITA trial represents the first randomized, double-blind, placebo-controlled study of oral vitamin C in patients with preleukemic conditions or low-risk bone marrow malignancies.1 While the supplementation did not substantially reduce the expansion of abnormal blood cells, it demonstrated encouraging survival advantages.1 More than half of trial participants had insufficient vitamin C levels at the study's start.1 The research was conducted across four hospitals: Copenhagen University Hospital–Rigshospitalet, Copenhagen University Hospital–Herlev, Aalborg University Hospital, and Keck Hospital of the University of Southern California.1
Researchers emphasize that larger Phase III clinical trials are needed to validate this potential survival benefit.1 The findings were published in the American Cancer Society journal CANCER (DOI: 10.1002/cncr.70549).1
评论
还没有评论，欢迎留下第一条。